Advanced

Parkinson's disease : Evolution of cognitive impairment and CSF Aβ1-42 profiles in a prospective longitudinal study

Lerche, Stefanie; Wurster, Isabel; Röben, Benjamin; Machetanz, Gerrit; Zimmermann, Milan; Bernhard, Felix; Stransky, Elke; Deuschle, Christian; Schulte, Claudia and Hansson, Oskar LU , et al. (2019) In Journal of Neurology, Neurosurgery and Psychiatry 90(2). p.165-170
Abstract

Objective: To evaluate the evolution of cognitive impairment in relation to cerebrospinal fluid (CSF) profiles of amyloid-β (Aβ), total-Tau and phosphorylated-Tau in Parkinson's disease (PD). Methods: Prospective, longitudinal, observational study up to 10 years with follow-up every 2 years. We assessed CSF profiles in 415 patients with sporadic PD (median age 66; 63% men) and 142 healthy controls (median age 62; 43% men). Results: Patients with PD with low CSF Aβ1-42 levels at baseline were more often cognitively impaired than patients with intermediate and high Aβ1-42 levels. Sixty-seven per cent of the patients with low Aβ1-42 levels at baseline and normal cognition developed cognitive impairment... (More)

Objective: To evaluate the evolution of cognitive impairment in relation to cerebrospinal fluid (CSF) profiles of amyloid-β (Aβ), total-Tau and phosphorylated-Tau in Parkinson's disease (PD). Methods: Prospective, longitudinal, observational study up to 10 years with follow-up every 2 years. We assessed CSF profiles in 415 patients with sporadic PD (median age 66; 63% men) and 142 healthy controls (median age 62; 43% men). Results: Patients with PD with low CSF Aβ1-42 levels at baseline were more often cognitively impaired than patients with intermediate and high Aβ1-42 levels. Sixty-seven per cent of the patients with low Aβ1-42 levels at baseline and normal cognition developed cognitive impairment during follow-up, compared with 41% and 37% of patients having intermediate and high CSF Aβ1-42 levels. Kaplan-Meier survival curves and Cox regression revealed that patients with low CSF Aβ1-42 levels at baseline developed cognitive impairment more frequently and earlier during follow-up. Conclusion: We conclude that in patients with sporadic PD, low levels of Aβ1-42 are associated with a higher risk of developing cognitive impairment earlier in the disease process at least in a subgroup of patients.

(Less)
Please use this url to cite or link to this publication:
author
, et al. (More)
(Less)
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
amyloid-beta, CSF, longitudinal, Parkinson
in
Journal of Neurology, Neurosurgery and Psychiatry
volume
90
issue
2
pages
165 - 170
publisher
BMJ Publishing Group
external identifiers
  • scopus:85053886033
ISSN
0022-3050
DOI
10.1136/jnnp-2018-318956
language
English
LU publication?
yes
id
df04979a-bed6-430e-ba21-b91db31ab4d4
date added to LUP
2018-10-22 13:58:23
date last changed
2019-05-27 18:25:20
@article{df04979a-bed6-430e-ba21-b91db31ab4d4,
  abstract     = {<p>Objective: To evaluate the evolution of cognitive impairment in relation to cerebrospinal fluid (CSF) profiles of amyloid-β (Aβ), total-Tau and phosphorylated-Tau in Parkinson's disease (PD). Methods: Prospective, longitudinal, observational study up to 10 years with follow-up every 2 years. We assessed CSF profiles in 415 patients with sporadic PD (median age 66; 63% men) and 142 healthy controls (median age 62; 43% men). Results: Patients with PD with low CSF Aβ<sub>1-42</sub> levels at baseline were more often cognitively impaired than patients with intermediate and high Aβ<sub>1-42</sub> levels. Sixty-seven per cent of the patients with low Aβ<sub>1-42</sub> levels at baseline and normal cognition developed cognitive impairment during follow-up, compared with 41% and 37% of patients having intermediate and high CSF Aβ<sub>1-42</sub> levels. Kaplan-Meier survival curves and Cox regression revealed that patients with low CSF Aβ<sub>1-42</sub> levels at baseline developed cognitive impairment more frequently and earlier during follow-up. Conclusion: We conclude that in patients with sporadic PD, low levels of Aβ<sub>1-42</sub> are associated with a higher risk of developing cognitive impairment earlier in the disease process at least in a subgroup of patients.</p>},
  author       = {Lerche, Stefanie and Wurster, Isabel and Röben, Benjamin and Machetanz, Gerrit and Zimmermann, Milan and Bernhard, Felix and Stransky, Elke and Deuschle, Christian and Schulte, Claudia and Hansson, Oskar and Zetterberg, Henrik and Gasser, Thomas and Berg, Daniela and Maetzler, Walter and Brockmann, Kathrin},
  issn         = {0022-3050},
  keyword      = {amyloid-beta,CSF,longitudinal,Parkinson},
  language     = {eng},
  number       = {2},
  pages        = {165--170},
  publisher    = {BMJ Publishing Group},
  series       = {Journal of Neurology, Neurosurgery and Psychiatry},
  title        = {Parkinson's disease : Evolution of cognitive impairment and CSF Aβ<sub>1-42</sub> profiles in a prospective longitudinal study},
  url          = {http://dx.doi.org/10.1136/jnnp-2018-318956},
  volume       = {90},
  year         = {2019},
}